New study aims to tame cholesterol side effect of lung cancer drug
NCT ID NCT07674524
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study looks at the best way to manage high cholesterol caused by the targeted therapy lorlatinib in people with advanced ALK-positive non-small cell lung cancer. Some participants receive standard cholesterol-lowering drugs, while others get a more intensive combination. The goal is to find a strategy that controls cholesterol without disrupting cancer treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rosuvastatin, Ezetimibe, Evolocumab
What this could lead to
If successful, this could establish a standard way to manage cholesterol side effects from lorlatinib, helping patients stay on their cancer treatment longer.
What could go wrong
This is a relatively small study focused on managing a side effect, not curing cancer. The intensive drug combination may cause additional side effects or not be widely adopted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••